<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1032">
  <stage>Registered</stage>
  <submitdate>13/01/2006</submitdate>
  <approvaldate>13/01/2006</approvaldate>
  <nctid>NCT00277537</nctid>
  <trial_identification>
    <studytitle>Safety and Efficacy of Bronchitol in Bronchiectasis</studytitle>
    <scientifictitle>A Phase III Multicenter, Randomised, Parallel, Placebo-Controlled, Double-Blind Study to Investigate the Safety and Efficacy of Treatment With Bronchitol (Dry Powder Mannitol) in the Symptomatic Treatment of Bronchiectasis.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>DPM-B-301</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Bronchiectasis</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Mannitol
Treatment: drugs - placebo

Experimental: 1 - 

Other: 2 - 


Treatment: drugs: Mannitol
320mg BD 12 weeks followed by 40 weeks open label

Treatment: drugs: placebo
BD for 12 weeks

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>24 hour sputum clearance</outcome>
      <timepoint>24 hours / 12 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Quality of Life SGRQ</outcome>
      <timepoint>12 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>bronchiectasis symptoms</outcome>
      <timepoint>12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>cough severity</outcome>
      <timepoint>12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>exercise capacity</outcome>
      <timepoint>12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>lung function, including gas transfer</outcome>
      <timepoint>12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>antibiotic use</outcome>
      <timepoint>12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>bronchial wall thickening and inflammation</outcome>
      <timepoint>12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>adverse events</outcome>
      <timepoint>12 weeks / 12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>haematology, biochemistry,</outcome>
      <timepoint>12 weeks / 12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>sputum microbiology quantitative and qualitative</outcome>
      <timepoint>12 weeks / 12 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Non cystic fibrosis bronchiectasis

          -  Have FEV1 50% - 80% predicted and =1.0L

          -  Have chronic sputum production of &gt;10 mL per day on the majority of days in the 3
             months prior to study entry</inclusivecriteria>
    <inclusiveminage>15</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Be using hypertonic saline or mucolytic pharmacological agents concurrently or in the
             4 weeks prior to study entry

          -  Have airway hyperresponsiveness as defined by a positive Aridol challenge</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/03/2006</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>354</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/07/2008</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>ACT,NSW,QLD,SA,VIC,WA</recruitmentstate>
    <hospital>Canberra Hospital - Canberra</hospital>
    <hospital>Royal Prince Alfred Hospital - Camperdown Sydney</hospital>
    <hospital>St George Hospital - Kogarah</hospital>
    <hospital>John Hunter Hospital - Newcastle</hospital>
    <hospital>Royal North Shore Hospital - St Leonards</hospital>
    <hospital>Bankstown Hospital - Sydney</hospital>
    <hospital>Mater Adult Hospital - Brisbane</hospital>
    <hospital>Cairns Base Hospital - Cairns</hospital>
    <hospital>Repatriation General Hospital - Adelaide</hospital>
    <hospital>Royal Adelaide Hospital - Adelaide</hospital>
    <hospital>Burnside War Memorial Hospital - Toorak Gardens, Adelaide</hospital>
    <hospital>Peninsula Health Frankston Hospital - Frankston</hospital>
    <hospital>The Alfred Hospital - Melbourne</hospital>
    <hospital>AARI Sir Charles Gairdner Hospital - Perth</hospital>
    <hospital>Royal Perth Hospital - Perth</hospital>
    <postcode> - Canberra</postcode>
    <postcode> - Camperdown Sydney</postcode>
    <postcode> - Kogarah</postcode>
    <postcode> - Newcastle</postcode>
    <postcode> - St Leonards</postcode>
    <postcode> - Sydney</postcode>
    <postcode> - Brisbane</postcode>
    <postcode> - Cairns</postcode>
    <postcode> - Adelaide</postcode>
    <postcode> - Toorak Gardens, Adelaide</postcode>
    <postcode> - Frankston</postcode>
    <postcode> - Melbourne</postcode>
    <postcode> - Perth</postcode>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Northern Ireland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Cambridge</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Leicester</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Manchester</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Norwich</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Pharmaxis</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Study will assess the safety and effectiveness of 12 week treatment with the study
      medication, Bronchitol, in subjects with bronchiectasis (a lung disease where patients have
      trapped, and often infected, thick, sticky mucus). Past studies have shown Bronchitol
      inhalation may help to facilitate the clearance of mucus by altering its rheology (making it
      less thick and sticky), thereby enhancing the shift of stagnant mucus from the lungs. On
      completion of the double blind phase, subjects will have the opportunity to participate in a
      52 week open label phase.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00277537</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Brett Charlton</name>
      <address>Pharmaxis Ltd Australia</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>